Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study-Reference-Cited by-同舟云学术

Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study

Published:2023-06-01 Issue:8 Volume:28 Page:1054-1062
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Dote Satoshi^ORCID,Shiwaku Eiji,Kohno Emiko,Fujii Ryohei,Mashimo Keiji,Morimoto Naomi,Yoshino Masaki,Odaira Naoki,Ikesue Hiroaki,Hirabatake Masaki,Takahashi Katsuyuki,Takahashi Masaya,Takagi Mari,Nishiuma Satoshi,Ito Kaori,Shimato Akane,Itakura Shoji,Takahashi Yoshitaka,Negoro Yutaka,Shigemori Mina,Watanabe Hiroyuki,Hayasaka Dai,Nakao Masahiko,Tasaka Misaki,Goto Emi,Kataoka Noriaki,Yokomizo Ayako,Kobayashi Ayako,Nakata Yoko,Miyake Mafumi,Hayashi Yaeko,Yamamoto Yoshie,Hirata Taiki,Azuma Kanako,Makihara Katsuya,Fukui Rino,Tokutome Akira,Yagisawa Keiji,Honda Shinji,Meguro Yuji,Suzuki Shota,Yamaguchi Daisuke,Miyata Hitomi,Kobayashi Yuka,

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-023-02357-3.pdf

Reference31 articles.

1. Tabernero J, Velez L, Trevino TL et al (2021) Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open. 6(6):100328. https://doi.org/10.1016/j.esmoop.2021.100328

2. SEER Cancer stat facts: colorectal cancer. https://seer.cancer.gov/statfacts/html/colorect.html. Accessed October 10, 2022

3. Kopetz S, Grothey A, Yaeger R et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 381(17):1632–1643. https://doi.org/10.1056/NEJMoa1908075

4. Nakamura Y, Okamoto W, Kato T et al (2021) Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med 27(11):1899–1903. https://doi.org/10.1038/s41591-021-01553-w

5. André T, Shiu KK, Kim TW et al (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383(23):2207–2218. https://doi.org/10.1056/NEJMoa2017699